ArticleClinical transplantation2025
Epidemiology, Treatment, and Outcomes of Gram-Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients.
Article in Clinical transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Outcomes of Short Antibiotic Courses for Gram-Negative Bloodstream Infections in Solid Organ Transplant Recipients-A Systematic Review and Meta-Analysis.Transplant infectious disease : an official journal of the Transplantation SocietyPooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLittle is known about the epidemiology and management of gram-negative bloodstream infections (GN-BSIs) in patients after solid organ transplant (SOT). We describe epidemiology, treatment approaches, and outcomes in a subset of patients with SOT from a larger cohort with GN-BSI.
methodsThis was a multicenter, retrospective cohort study that enrolled unique, consecutive adults with GN-BSI hospitalized at any of 24 participating hospitals between January and December 2019.
resultsOf 4581 adults in the overall cohort, 298 (6.5%) were SOT recipients, including kidney (177, 59%), liver (67, 22%), heart (23, 8%), lung (12, 4%), and multiorgan (19, 6%) recipients. The most common organisms were Escherichia coli (45%), Klebsiella pneumoniae (20%), and Pseudomonas aeruginosa (15%). Twenty-two percent of E. coli, Klebsiella spp., or Proteus spp. isolates had extended-spectrum beta-lactamase phenotype. Sixty-six (22%) subjects did not receive active empirical therapy within the first 48 h. Median treatment duration was 15 days (IQR 12-18 days). Transition to oral therapy occurred in 161 (54%) patients at a median of 4 days (IQR 3-7 days). Thirty-one patients (10%) had recurrent bacteremia, and 10% of the cohort died within 90 days. DISCUSSION: In this large cohort of SOT patients with GN-BSI, durations exceeded 14 days in most patients, while more than half transitioned to oral antibiotics. Approximately 1 in 5 did not receive active empirical antibiotics, highlighting the impact of drug resistance and the importance of access to rapid diagnostic tools in this patient population. Mortality aligned with published estimates from other studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.